Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 11/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29129593 | 0.81 | RXRA (0.47) | RXRARXRBRXRGARTAS2R14 | |
| SCHEMBL28465111 | 0.81 | RXRA (0.49) | RXRARXRBRXRGAR | |
| SCHEMBL3544782 | 0.80 | P2RX7 (0.52) | TGM2 | |
| SCHEMBL23274113 | 0.78 | RXRA (0.48) | RXRARXRBRXRGAR | |
| SCHEMBL21924973 | 0.77 | TGM2 (0.54) | TGM2ARTAS2R14 | |
| SCHEMBL28084056 | 0.75 | RXRA (0.63) | RXRARXRBRXRGARTAS2R14 | |
| SCHEMBL12984770 | 0.74 | RXRA (0.79) | RXRARXRBRXRGARTAS2R14 | |
| SCHEMBL20456248 | 0.73 | TGM2 (0.63) | TGM2 | |
| SCHEMBL10194672 | 0.73 | TGM2 (0.63) | TGM2 | |
| SCHEMBL28084058 | 0.73 | RXRA (0.54) | RXRARXRBRXRGAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119529932-A | High-adhesion port machine lubricating grease and preparation method thereof | 虎牌石油（中国）有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-117071028-A | Aluminum alloy profile surface treatment process | 宁波锦华铝业有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-8895772-B2 | Process for preparing bicalutamide | SHILPA MEDICARE LIMITED (IN) | 2014-11-25 | — | — | US | disclosed |
| US-20130274501-A1 | PROCESS FOR PREPARING BICALUTAMIDE | SHILPA MEDICARE LIMITED (IN) | 2013-10-17 | — | — | US | disclosed |
| WO-2012042532-A1 | PROCESS FOR PREPARING BICALUTAMIDE | SHILPA MEDICARE LIMITED (IN) | 2012-04-05 | — | — | WO | disclosed |
| US-20080177109-A1 | Novel Process for Preparation of Bicalutamide | USV LIMITED (IN) | 2008-07-24 | — | — | US | disclosed |
| EP-1863759-A1 | PROCESS FOR PREPARATION OF BICALUTAMIDE | USV LIMITED (IN) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006103689-A1 | PROCESS FOR PREPARATION OF BICALUTAMIDE | USV LIMITED (IN) | 2006-10-05 | — | — | WO | disclosed |
| EP-1322603-A1 | PROCESS FOR THE PREPARATION OF N-(SUBSTITUTED PHENYL)-3-ALKYL-, ARYL- AND HETEROARYLSULFONYL-2-HYDROXY-2-ALKYL- AND HALOALKYLPROPANAMIDE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6562994-B2 | Reacting a substituted halo- or sulfonylbenzene with an alpha, beta unsaturated propanamide; followed by epoxidation, reacting with a thiol and oxidizing; no chromatographic separations; uses less expensive starting materials | BRISTOL-MYERS SQUIBB CO. | 2003-05-13 | — | — | US | disclosed |
| US-20020086902-A1 | Process for the preparation of N-(substituted phenyl)-3-alkyl-,aryl- and heteroarylsulfonyl-2-hydroxy-2-alkyl-and haloalkylpropanamide compounds | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-04 | — | — | US | disclosed |
| WO-2002024638-A1 | PROCESS FOR THE PREPARATION OF N-(SUBSTITUTED PHENYL)-3-ALKYL-, ARYL- AND HETEROARYLSULFONYL-2-HYDROXY-2-ALKYL- AND HALOALKYLPROPANAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086902-A1 | Process for the preparation of N-(substituted phenyl)-3-alkyl-,aryl- and heteroarylsulfonyl-2-hydroxy-2-alkyl-and haloalkylpropanamide compounds | NR5A1, CYP17A1, CYP19A1 | RXRA 1797/4885RXRB 2346/4885RXRG 2964/4885 |
| US-20130274501-A1 | PROCESS FOR PREPARING BICALUTAMIDE | NR5A1, AR, SRD5A1 | RXRA 4244/4885RXRB 3914/4885RXRG 4214/4885 |
| US-20080177109-A1 | Novel Process for Preparation of Bicalutamide | PKD1, CYP11A1, CBR3 | RXRA 4670/4885RXRB 4650/4885RXRG 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.